TMS Co

TMS Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of TMS Co (4891.T) as of Nov 4, 2026 is -29.19 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -29.94 % — a change of -2.49% (higher).

EBIT/Assets

-29.19 %

YoY

-2.49%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of TMS Co is 2026 -29.19 % . Operating Income to Assets Ratio (EBIT/Assets) of TMS Co was 2025 -29.94 % . It decreases by -2.49% higher compared to the previous year.

The TMS Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2021
-59.44 JPY
Jan 1, 2022
41.45 JPY
Jan 1, 2023
-13.72 JPY
Jan 1, 2024
-26.53 JPY
Jan 1, 2025
-29.94 JPY
Jan 1, 2026
-29.19 JPY
The TMS Co EBIT/Assets history
YEAREBIT/AssetsYoY
-29.19 %-2.49%
-29.94 %+12.82%
-26.53 %+93.35%
-13.72 %-133.11%
41.45 %-169.74%
-59.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Operating Income to Assets Ratio (EBIT/Assets) of TMS Co is -29.19 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of TMS Co changed from -29.94 % to -29.19 %, representing a -2.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) TMS Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s TMS Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — TMS Co

All Key Metrics — TMS Co